Clinical trials: Haemorrhage
Hemorrhage, Atrial Fibrillation, Postoperative
Prevention of Retained-Blood Outcomes With Active Clearance Technology
Postoperative bleeding is a common consequence after heart surgery which can significantly impact outcomes and costs . When bleeding occurs, reliable postoperative blood evacuation of the pleural, mediastinal and pericardial…
- Trial name
- NCT02145858
- Testing
- Blood drainage post cardiac surgery using PleuraFlow System
- Where
- 2 sites in United States
- Volunteers
- 891 people
- Sponsor
- ClearFlow, Inc.
Periodontal Diseases, Gingivitis
Randomized Trial of a Gum Health Formulation
The purpose of this study is to evaluate the safety and efficacy of a newly formulated foaming gel product on gingivitis and/or moderate periodontitis when used with or without the GLO Science accelerating device (GLO Device)…
- Conditions
- Periodontal Diseases, Gingivitis, Periodontitis, Halitosis
- Trial name
- NCT03196648
- Testing
- Gingival health formulation in an accelerating device, Gingival health formulation on a toothbrush, OTC fluoride toothpaste
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Glo Science, Inc.
Haemophilia A
A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®
This study will collect information on side effects and how well Esperoct® (turoctocog alfa pegol (N8-GP)) works during long-term treatment (prophylaxis) in males with haemophilia A.
- Trial name
- pathfinder9 (NCT04574076)
- Testing
- Turoctocog alfa pegol (N8-GP)
- Where
- 27 sites in Austria, Bulgaria and 13 more
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
Blood Transfusion, Blood Transfusion, Autologous
A Study to Determine the Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Non-anemic Patients Who Are Undergoing Orthopedic, Heart and Blood Vessel, or Breast Reduction Surgery; Performed in Combination With a Procedure to Reduce Blood Loss During Surgery.
The purpose of this study is to determine the safety and effectiveness of epoetin alfa and whether epoetin alfa will enable self-donation of blood during an 11-day period before surgery (which is shorter than the conventional…
- Conditions
- Blood Transfusion, Blood Transfusion, Autologous, Orthopedic Procedures, Orthopedic Surgery
- Trial name
- NCT00270023
- Testing
- epoetin alfa
- Volunteers
- 112 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Severe Postpartum Haemorrhage
A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in India
This study will look at how safe is the medicine eptacog alfa when used in women in India for stopping heavy bleeding after giving birth.
- Trial name
- NCT07157423
- Testing
- Eptacog alfa (NovoSeven)
- Where
- 14 sites in India
- Volunteers
- 64 people
- Sponsor
- Novo Nordisk A/S
Aneurysmal Subarachnoid Hemorrhage (aSAH), Headache Disorders
Efficacy of Scalp Block in Managing Post Subarachnoid Hemorrhage Headache in Critically Ill Patients. A Single Centre Randomized Controlled Trial
Subarachnoid hemorrhage (SAH) is a devastating neurological disorder associated with significant mortality and morbidity rates, arising not just from the hemorrhage itself but also because of the catastrophic multisystem sequelae…
- Trial name
- SAH-BLOCK (NCT07307508)
- Testing
- Levobupivacaine Scalp block, Conventional analgesic therapy
- Where
- Qatar
- Volunteers
- 22 people
- Sponsor
- Hamad Medical Corporation
Acquired Bleeding Disorder, Trauma
Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma Patients
This trial is conducted in Africa, Asia, Europe, Oceania and North America. The aim of this trial is to evaluate the efficacy of activated recombinant human factor VII given in conjunction with standard therapy in the treatment…
- Trial name
- NCT01563523
- Testing
- activated recombinant human factor VII
- Where
- 9 sites in Australia, Austria and 7 more
- Volunteers
- 283 people
- Sponsor
- Novo Nordisk A/S
Purpura, Thrombocytopenic, Idiopathic
Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)
The purpose of this study is to determine whether Fostamatinib Disodium is safe and effective in the treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP).
- Trial name
- NCT00706342
- Testing
- Fostamatinib Disodium / R935788
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Rigel Pharmaceuticals
Leiomyoma, Uterine Fibroids
Fibroid Ablation Study
The primary objective of this study is to establish the effectiveness and confirm the safety of the VizAblate System in ablating symptomatic uterine fibroids.
- Conditions
- Leiomyoma, Uterine Fibroids, Menorrhagia
- Trial name
- FAST-EU (NCT01226290)
- Testing
- VizAblate System
- Where
- 10 sites in Mexico, Netherlands and 1 more
- Volunteers
- 51 people
- Sponsor
- Gynesonics
Venous Thromboembolism
YM150 for Prevention of Venous Thromboembolism in Patients With Acute Medical Illness
To evaluate the safety and efficacy of the oral dose of YM150 for prevention of venous thromboembolism (VTE) in patients with acute medical illness.
- Trial name
- NCT01028950
- Testing
- YM150
- Where
- 5 sites in Japan
- Volunteers
- 52 people
- Sponsor
- Astellas Pharma Inc
Contraception
GA Levonorgestrel Intrauterine Contraceptive System (LCS) Phase III Study China
The purpose of this study is to assess the efficacy, safety, bleeding pattern of low dose LNG (12 mg/ 24 hrs), delivered locally by a new intrauterine contraceptive system suitable for use by women 18 to 40 years of age.
- Trial name
- NCT00884260
- Testing
- Levonorgestrel IUS (LCS, BAY86-5028)
- Where
- 25 sites in Australia, China and 1 more
- Volunteers
- 918 people, healthy volunteers welcome
- Sponsor
- Bayer
Immune Thrombocytopenia
Extension Study of Herombopag for Pediatric Patients With Chronic Immune Thrombocytopenia
The main purpose of this extended study is to enable subjects who are currently receiving the PartB experimental drug in the HR-TPO-ITP-III-PED clinical trial .To continue receiving the experimental drug after the completion of…
- Trial name
- NCT05685420
- Testing
- Herombopag
- Volunteers
- 117 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Aortic Aneurysm
Haemocomplettan® P During Aortic Replacement
The primary purpose is to show that administration of Haemocomplettan® P significantly reduces the amount of blood products needed during aortic surgery.
- Trial name
- NCT00701142
- Testing
- Haemocomplettan® P, Saline solution
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- CSL Behring
Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB)
HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB
The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacodynamics (PD) of multiple doses of ALN-6400 in adult and adolescent patients with VWD and HMB
- Trial name
- HMBeacon (NCT07575308)
- Testing
- ALN-6400
- Where
- 21 sites in United States, Netherlands and 3 more
- Volunteers
- 24 people
- Sponsor
- Alnylam Pharmaceuticals
Bleeding, Surgical Wound
Traumacel FAM Trium in the Post-market Surveillance Phase
The investigational medical device Traumacel FAM Trium is a sterile plant polysaccharide haemostatic agent based on the oxidized cellulose in the form of multilayer nonwoven fabric.
- Trial name
- NCT05177874
- Testing
- Traumacel FAM Trium, Surgicel Fibrillar
- Where
- Czechia
- Volunteers
- 98 people
- Sponsor
- Bioster, a.s.
Congenital Fibrinogen Deficiency
Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery
The purpose of the study is to assess the efficacy and safety of Octafibrin for on-demand treatment of acute bleeding in subjects with congenital fibrinogen deficiency.
- Trial name
- NCT02267226
- Testing
- Octafibrin
- Where
- 12 sites in United States, Bulgaria and 7 more
- Volunteers
- 25 people
- Sponsor
- Octapharma
Postpartum Haemorrhage (PPH)
Temporary Aortic Occlusion With the Abdominal Tourniquet for Refractory Postpartum Haemorrhage: A Proof-of-Concept Study in a War-Affected Region
The purpose of this study is to evaluate whether a medical device called the Abdominal Aortic and Junctional Tourniquet - Stabilized (AAJT-S) can safely and effectively temporarily stop severe bleeding after childbirth (known as…
- Trial name
- TAOAT (NCT07016568)
- Testing
- Abdominal Aortic and Junctional Tourniquet - Stabilized (AAJT-S)
- Where
- Ukraine
- Volunteers
- 4 people
- Sponsor
- LLC UkrMedGroup
Coagulation Defects
Safety Study of Spray-Dried Solvent/Detergent-Treated Plasma for Infusion in Healthy Volunteers
This study is a Phase 1, single-center, open-label, ascending dose study which will assess the safety and tolerability of 5 doses of spray-dried solvent/detergent treated plasma (Resusix®) in healthy volunteers.
- Trial name
- NCT01589666
- Testing
- Spray-dried S/D-treated Plasma
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Entegrion, Inc.
Venous Thromboembolism
A Comparison of Extended Versus Conventional Duration of Enoxaparin Prophylaxis (i.e., Preventive Treatment) for Venous Thromboembolism (VTE, i.e., Blood Clots in the Veins) and Bleeding Event Risk in a Population With Acute Medical Illness
Venous Thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is associated with an increase in risk of mortality and long-term disability and is a major contributor to global disease burden.
- Trial name
- NCT05819112
- Where
- United States
- Volunteers
- 14,799 people
- Sponsor
- Sanofi
Heavy Menstrual Bleeding, Abnormal Uterine Bleeding
A Registry to Gather Real World Use Data on the Cerene® Cryotherapy Device
Channel Medsystems, Inc., the manufacturer of the Cerene® Cryotherapy Device (Cerene), is initiating a prospective, observational registry, the Progress registry, to gather data during real world utilization of the Cerene®…
- Conditions
- Heavy Menstrual Bleeding, Abnormal Uterine Bleeding, Menorrhagia
- Trial name
- Progress (NCT05922657)
- Testing
- Cerene
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Channel Medsystems